Cellectis
Yahoo Finance • 2 days ago
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading
European equities traded in the US as American depositary receipts were trending lower late Thursday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 15 days ago
European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading
European equities traded in the US as American depositary receipts were tracking lower late Friday morning, declining 0.35% to 1,962.14 on the S&P Europe Select ADR Index, which is up 0.17% for the week so far.From continental Europe, the... Full story
Yahoo Finance • 16 days ago
European Equities Traded in the US Rise in Thursday Trading
European equities traded in the US as American depositary receipts were higher late Thursday morning, rising 0.45% to 1,969.72 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by biopharmaceutical company C... Full story
Yahoo Finance • last month
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
European equities traded in the US as American depositary receipts were tracking higher late Wednesd PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 2 months ago
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Healthcare is changing through AI and personalized cell therapy. Which of these high-growth innovators represents the better risk-adjusted opportunity for your portfolio today as you evaluate Heartflow Inc. (NASDAQ:HTFL) and Iovance Biothe... Full story
Yahoo Finance • 3 months ago
Ferretti Leads The Charge In European Penny Stock Opportunities
European markets recently showed a lack of clear direction, with the pan-European STOXX Europe 600 Index declining slightly as investors weighed geopolitical developments and economic data. Despite these broader market uncertainties, there... Full story
Yahoo Finance • 3 months ago
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapi... Full story
Yahoo Finance • 3 months ago
Cellectis présente les résultats finaux de phase 1 pour lasmé-cel et des résultats préliminaires pour éti-cel au congrès de l’EHA 2026
NEW YORK, 11 juin 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des thérapies cellulaires e... Full story
Yahoo Finance • 3 months ago
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapi... Full story
Yahoo Finance • 3 months ago
Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire
NEW YORK, 09 juin 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des thérapies cellulaires e... Full story
Yahoo Finance • 4 months ago
Cellectis to Report First Quarter Financial Results on May 11, 2026
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies... Full story
Yahoo Finance • 4 months ago
Cellectis publiera ses résultats financiers du premier trimestre le 11 mai 2026
NEW YORK, 04 mai 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des thérapies cellulaires et... Full story
Yahoo Finance • 4 months ago
European Equities Traded in the US as American Depositary Receipts Declining in Thursday Trading
European equities traded in the US as American depositary receipts were trending lower late Thursday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 5 months ago
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
European equities traded in the US as American depositary receipts were tracking lower late Thursday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 5 months ago
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
On February 17, 2026, B Group, Inc. disclosed a new position in Structure Therapeutics(NASDAQ:GPCR), acquiring 90,000 shares in the fourth quarter. What happened B Group disclosed in a Securities and Exchange Commission (SEC) filing date... Full story
Yahoo Finance • 5 months ago
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 population In target Phase 2 population: 100% of patients became eligible to transplantPivotal Phase 2 first... Full story
Yahoo Finance • 5 months ago
Cellectis publie ses résultats financiers du quatrième trimestre 2025 et de l’exercice 2025 et une mise à jour de ses activités
Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) en cours Phase 1 : 83 % d’ORR à la dose RP2D et 100 % d’ORR dans la population cible de phase 2.Population cible de phase 2 : 100 % des patients son... Full story
Yahoo Finance • 6 months ago
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapi... Full story
Yahoo Finance • 6 months ago
Cellectis publiera ses résultats financiers du quatrième trimestre et de l’année 2025 le 19 mars 2026
NEW YORK, 12 mars 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer des thérapies innov... Full story
Yahoo Finance • 7 months ago
European Equities Traded in the US as American Depositary Receipts Little Changed in Tuesday Trading
European equities traded in the US as American depositary receipts were little changed late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story